OrbusNeich Garners “HKCT Business Awards 2024 – Most Outstanding Medical Group of the Year” and “Health Partnership Awards 2024 – Outstanding Innovative Medical Device Solutions” Committed to Providing Innovative Solutions for Medical Device Dedicated to Improving Global Public Health

(Hong Kong, 4 November, 2024) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, has recently won the “Most Outstanding Medical Group of the Year” at the “HKCT Business Awards 2024”, as well as the “Outstanding Innovative Medical Device Solution” at the “Health Partnership Awards 2024” organized by a well-known Hong Kong financial media outlet ET Net. Alongside endorsing its outstanding performance in developing innovative endovascular and structural heart interventional products and commitment to providing more comprehensive medical solutions over the past year, the awards also represent the significant recognition of the Group’s contribution to improving global public health.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “We are deeply honored that the entire Group’s tireless efforts over the past year have garnered attention and recognition from various sectors. With a steadfast commitment to medical device innovation, OrbusNeich currently holds over 230 granted patents and published patent applications worldwide. Our continuous launch of various products into global markets has benefited patients across more than 70 countries and regions. With the high-capacity logistics center in the Netherlands in operation, and the resumption of production at the factory in Germany, along with the anticipated commissioning of our largest R&D and manufacturing facility in Hangzhou in 2027 which will double our existing production capacity, we believe we will benefit more patients worldwide. Looking ahead, we remain dedicated to innovation, striving to deliver high-quality vascular intervention solutions that effectively support the clinical needs of patients and continuously improve their quality of life.”

The “HKCT Business Awards” themed “Uniting Hong Kong’s Strengths, Creating Business Opportunities”. is organized by Hong Kong Commercial Times. Award-winning companies are thoroughly evaluated by the judging panel based on four criteria: corporate achievements, market competitiveness, brand philosophy, and professional status. This evaluation recognizes their efforts and accomplishments over the past year and to encourage enterprises to keep enhancing their market competitiveness and exploring new economic directions.

Organized by the Hong Kong financial information platform ET Net, this year’s “Health Partnership Awards” featured the theme “Healthy Asset as Extraordinary Wealth”. The award aims to raise public awareness about the importance of healthy living and quality wealth management, while also honoring individuals and organizations that have made outstanding contributions to healthcare, financial products, and society, especially in promoting healthy lifestyles and enhancing community welfare.

OrbusNeich wins the “HKCT Business Awards 2024 –  “Most Outstanding Medical Group of the Year”

Ms. Maggie Lau, Corporate Communications Manager of OrbusNeich, receives the “Health Partnership Awards 2024” on behalf of the Group

－ End －

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into neuro vascular intervention and structural heart disease. As of June 30, 2024, OrbusNeich has more than 230 granted patents and published patent applications worldwide. Its in-house R&D team has more than two decades of product development experience and has developed world-leading proprietary technologies.